登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H34O5
化学文摘社编号:
分子量:
354.48
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
212-017-2
Beilstein/REAXYS Number:
5294062
MDL number:
产品名称
前列地尔, European Pharmacopoeia (EP) Reference Standard
InChI key
GMVPRGQOIOIIMI-DWKJAMRDSA-N
InChI
1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
SMILES string
O=C1[C@H](CCCCCCC(O)=O)[C@@H](/C=C/[C@H](CCCCC)O)[C@H](O)C1
grade
pharmaceutical primary standard
API family
alprostadil
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−20°C
Gene Information
human ... PTGER1(5731), PTGER2(5732)
正在寻找类似产品? 访问 产品对比指南
Application
Alprostadil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
hcodes
pcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Takashi Onoe et al.
Transplantation, 95(12), 1521-1527 (2013-04-20)
Small-for-size syndrome remains the greatest limiting factor of expanding segmental liver transplantation from living donors. Portal hyperperfusion is considered to substantially contribute to small-for-size syndrome. We investigated the impact of continuous portal infusion of prostaglandin E1 (PGE1) on small-for-size grafts
Pierre Costa et al.
Drugs, 72(17), 2243-2254 (2012-11-23)
The global burden of erectile dysfunction (ED) is increasing. It is estimated that 8-19% of men in Europe have ED and that by 2025 the prevalence of ED worldwide will reach 322 million. The gold standard therapy for ED is
A Creutzig et al.
VASA. Zeitschrift fur Gefasskrankheiten, 33(3), 137-144 (2004-10-06)
The relevance of Prostaglandin El (PGE,) in the treatment of peripheral arterial occlusive disease stage III and IV was to be evaluated for the first time by a meta-analysis. Altogether, 643 patients were analyzed from seven randomized, controlled PGE1 studies
Mikkel Fode et al.
BJU international, 112(7), 998-1008 (2013-07-06)
The pathophysiology of erectile dysfunction after radical prostatectomy (RP) is believed to include neuropraxia, which leads to temporarily reduced oxygenation and subsequent structural changes in penile tissue. This results in veno-occlusive dysfunction, therefore, penile rehabilitation programmes focus on tissue oxygenation.
Yasuyuki Hara et al.
The Journal of surgical research, 184(2), 1134-1142 (2013-05-22)
To resolve the shortage of donors associated with liver transplantation, the potential uncontrolled non-heart-beating donor (UNHBD) pool is expected to increase. However, warm ischemia-reperfusion injury leads to inferior survival in transplantation using the grafts from UNHBD compared with those from
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持